HLS Insider Trading

Insider Ownership Percentage: 0.37%
Insider Buying (Last 12 Months): C$112,988.00
Insider Selling (Last 12 Months): C$0.00

HLS Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at HLS Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HLS Therapeutics Share Price & Price History

Current Price: C$3.71
Price Change: Price Decrease of -0.06 (-1.59%)
As of 10/10/2024 11:38 AM ET

This chart shows the closing price history over time for HLS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

HLS Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/14/2024John Gordon HannaDirectorBuy1,200C$3.19C$3,828.00
5/15/2024Craig MillianDirectorBuy2,500C$2.90C$7,250.00
11/16/2023Craig MillianDirectorBuy5,000C$2.60C$13,000.00
11/15/2023Brian Thomas WalshSenior OfficerBuy1,000C$2.91C$2,910.00
11/10/2023Polar Asset Management Partners Inc.InsiderBuy20,000C$4.30C$86,000.00
5/19/2023Tim HendricksonSenior OfficerBuy2,500C$4.50C$11,250.00
5/12/2022William M. WellsDirectorSell50,000C$12.51C$625,710.00838,575
12/13/2021Tim HendricksonSenior OfficerBuy400C$14.63C$5,852.0042,900
See Full Table

SEC Filings (Institutional Ownership Changes) for HLS Therapeutics (TSE:HLS)

65.20% of HLS Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

HLS Therapeutics logo
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.
Read More on HLS Therapeutics

Today's Range

Now: C$3.71
Low: C$3.71
High: C$3.76

50 Day Range

MA: C$3.33
Low: C$3.01
High: C$3.94

52 Week Range

Now: C$3.71
Low: C$3.00
High: C$5.48

Volume

1,250 shs

Average Volume

24,219 shs

Market Capitalization

C$117.94 million

P/E Ratio

N/A

Dividend Yield

4.30%

Beta

1.07

Who are the company insiders with the largest holdings of HLS Therapeutics?

HLS Therapeutics' top insider investors include:
  1. Brian Thomas Walsh (Senior Officer)
  2. Craig Millian (Director)
  3. John Gordon Hanna (Director)
  4. Polar Asset Management Partners Inc (Insider)
  5. Tim Hendrickson (Senior Officer)
Learn More about top insider investors at HLS Therapeutics.